BioCentury | Dec 11, 2019
Product Development

The writing has been on the wall for Sanofi’s diabetes, CV business for years

...in China in 2020, based on securing reimbursement for Plavix clopidogrel and hypertension drug Co-Aprovel irbesartan/hydrochlorothiazide...
BioCentury | Sep 26, 2019
Politics & Policy

MNCs gain ground in China’s centralized procurement

...therapy Alimta pemetrexed; and Sanofi (Euronext:SAN; NASDAQ:SNY), which won its bid for hypertension drug Irtra irbesartan/hydrochlorothiazide...
BioCentury | Sep 25, 2019
Politics & Policy

Additional price cuts in nationwide expansion of China’s centralized procurement

...was up RMB0.45 to RMB15.54. The company announced it won bids for seven products: irbesartan, irbesartan/hydrochlorothiazide...
BioCentury | Dec 7, 2018
Company News

Chinese biopharma stocks plummet after centralized tendering report

...program, including a 90% cut for antiviral entecavir and a 60% cut for hypertension drug irbesartan...
BioCentury | Dec 7, 2018
Company News

Chinese biopharma stocks plummet after centralized tendering report

...program, including a 90% cut for antiviral entecavir and a 60% cut for hypertension drug irbesartan...
BioCentury | Sep 12, 2018
Politics & Policy

China biopharma stocks fall after centralized tendering talks

...Among those are Lipitor atorvastatin and Amlodin amlodipine besilate from Pfizer Inc. (NYSE:PFE), and Aprovel irbesartan...
BioCentury | Feb 17, 2017
Targets & Mechanisms

Gilding the Goldfinch

...angiotensin and endothelin receptor antagonist (DARA) FSGS Phase II Dimerix Ltd. (ASX:DXB) DMX-200 Therapy comprising irbesartan...
BioCentury | Oct 24, 2016
Clinical News

Propagermanium and irbesartan: Interim Phase II data

...of up to 30 patients to receive thrice-daily DMX-200, comprised of standard of care (SOC) irbesartan...
...final data from part A in 2H17. Dimerix Ltd. (ASX:DXB), Melbourne, Australia Product: Propagermanium and irbesartan...
...type 1 (AT1) receptor (AGTR1) ; CC chemokine receptor 2 (CCR2) (CD192) Description: Therapy comprising irbesartan...
BioCentury | Sep 12, 2016
Clinical News

Sparsentan: Phase II data

...from baseline to week 8 vs. irbesartan (44.8% vs. 18.5%, p=0.006). Patients received 300 mg irbesartan...
...n=51), mean proteinuria was reduced from baseline to week 8 by 47.4% vs. 19% for irbesartan...
BioCentury | Sep 7, 2016
Clinical News

Retrophin jumps on Phase II FSGS data

...combined 44.8% reduction of proteinuria, compared with an 18.5% reduction for patients who received oral irbesartan...
Items per page:
1 - 10 of 65